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Abstract
Introduction: Deficiencies in cellular responses to DNA
damage can predispose to cancer. Ionizing radiation can cause
cluster damage and double-strand breaks (DSBs) that pose
problems for cellular repair processes. Three genes (ATM,
BRCA1, and BRCA2) encode products that are essential for
the normal cellular response to DSBs, but predispose to breast
cancer when mutated.
Design: To examine the joint roles of radiation exposure and
genetic susceptibility in the etiology of breast cancer, we
designed a case-control study nested within five population-
based cancer registries. We hypothesized that a woman carrying
a mutant allele in one of these genes is more susceptible to
radiation-induced breast cancer than is a non-carrier. In our
study, 700 women with asynchronous bilateral breast cancer
were individually matched to 1400 controls with unilateral breast
cancer on date and age at diagnosis of the first breast cancer,
race, and registry region, and counter-matched on radiation
therapy. Each triplet comprised two women who received
radiation therapy and one woman who did not. Radiation
absorbed dose to the contralateral breast after initial treatment
was estimated with a comprehensive dose reconstruction
approach that included experimental measurements in
anthropomorphic and water phantoms applying patient treatment
parameters. Blood samples were collected from all participants
for genetic analyses.
Conclusions: Our study design improves the potential for
detecting gene–environment interactions for diseases when
both gene mutations and the environmental exposures of
interest are rare in the general population. This is particularly
applicable to the study of bilateral breast cancer because both
radiation dose and genetic susceptibility have important
etiologic roles, possibly by interactive mechanisms. By using
counter-matching, we optimized the informativeness of the
collected dosimetry data by increasing the variability of
radiation dose within the case–control sets and enhanced our
ability to detect radiation–genotype interactions.
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Introduction
The WECARE (for Women’s Environmental Cancer and
Radiation Epidemiology) Study is a multi-center,
population-based case-control study of breast cancer
designed to examine the interaction of gene carrier status
and radiation exposure in the etiology of breast cancer.
We are currently focusing on three major breast cancer
susceptibility genes: ATM,  BRCA1, and BRCA2. Our
underlying hypothesis is that a woman who carries a
mutant variant of one of these three genes is more
susceptible to radiation-induced breast cancer than a
woman who is not a carrier. In addition, the repository of
specimens and data that are currently being assembled
make it possible to evaluate at a later date a broad range
of other genes that lie in related cellular response
pathways. This  paper addresses the theoretical and
practical issues we faced in designing this study to
improve cost efficiency and feasibility. Specifically, our
study power was enhanced by selecting a genetically
enriched study population predisposed to breast cancer,
by using a counter-matched design, and by developing a
dose reconstruction method to reduce the error in
estimating individual radiation exposure derived from
imperfect and old medical records. These considerations,
coupled with our current understanding of radiogenic
breast cancer and genetic susceptibility, provide the
basis for the multi-disciplinary WECARE Study,
encompassing epidemiologic risk factor information,
genetic analyses of large complex genes, and estimation
of radiation-absorbed dose to breast tissue.
Background on DNA damage response genes, ionizing
radiation, and breast cancer susceptibility
So far, all of the genes known to be associated with
increased susceptibility to breast cancer function within
DNA damage response pathways. ATM, the product of
the gene mutated in the autosomal recessive disorder
ataxia–telangiectasia, has a critical function in signaling
the presence of DNA double-strand breaks (DSBs) that
are induced by ionizing radiation, radiomimetic chemicals,
and developmental DNA rearrangement events [1]. Upon
activation by ionizing radiation or other DSB-inducing
agents, ATM phosphorylates many downstream targets
that control pathways whose activation can result in DNA
repair, cell cycle checkpoint control, and apoptosis [2].
These targets include the products of several genes
implicated in breast cancer susceptibility such as BRCA1
[3,4] and CHEK2 [5–7]. There has been evidence from
epidemiologic studies of ataxia–telangiectasia families
[8,9], mutation screening of ATM in breast cancer
cohorts [10–12], and animal models [13] that carrier
status for at least a subset of ATM mutations is also
associated with an increased risk for breast cancer.
However, the mechanism mediating this increased risk
and the potential involvement of radiation exposure have
yet to be elucidated.
Ionizing radiation can cause DNA damage that may, in
sufficient dosage, result in mutations in oncogenes and
tumor suppressor genes [14,15]. It is a known breast
carcinogen, especially when exposure occurs before age
40 years when excess risks range from 5.5 to 10.7 cases
per 104 woman-years/Gy [16,17]. Studies with long-term
follow-up, examining different radiation doses and types of
exposure, have shown that the risk for developing radio-
genic breast cancer is similar for single and fractionated
exposures, provided that they represent equal total radiation
doses [18–20]. The increased risk is directly proportional
to increasing radiation dose, inversely related to age at
irradiation, and remains elevated throughout life [21]. For
example, among women exposed to radiation between the
ages of 10 and 39 years, increased relative risks (RRs) are
first seen about 10–15 years after exposure and do not
diminish for 35–50 years [21,22]. Very high therapeutic
doses received by young women during the treatment of
Hodgkin’s disease have recently been shown to increase
breast cancer risk in a dose-dependent manner [23]. In
our study, we focus on the radiation dose received to the
contralateral breast (CB) during breast treatment, which
ranges from about 1.0 to 7.1 Gy [24–27]. Because many
irradiated cells in the CB survive, radiation-induced DNA
damage may increase the probability that a tumor may
develop in this breast. Findings from the most compre-
hensive study to date showed that exposure to such
radiation to the CB from radiation therapy (RT) increased
the risk of developing second primary breast cancer
among young women (RR = 1.59, 95% confidence
interval 1.07–2.36) and among those who survived at
least 10 years after RT (RR = 1.85, 95% confidence
interval 1.15 to 2.97) [27]. The goal of the WECARE
Study is to examine whether subgroups of women with
breast cancer are at heightened risk for developing a
second primary breast cancer after RT because of a
genetic susceptibility, namely a mutation in ATM, BRCA1,
or BRCA2.
Second primary breast cancer – a useful context in
which to study gene–environment and gene–gene
interactions
For susceptibility genes, such as BRCA1 and  BRCA2,
the low prevalence of mutation carriers and of selected
environmental risk factors limits the informativeness of
studies conducted with a random sample obtained from
the general population (for example, traditional case-
control designs). The WECARE Study was based on the
premise that by restricting consideration to women with a
first primary breast cancer and then studying the
determinants of developing a second primary breast
cancer, the power to detect main effects of relatively rare
genetic mutations and their interactions with environ-
mental factors is considerably enhanced. This enhance-
ment results because any genetic abnormality that is
important in the etiology of breast cancer would beR201
considerably more prevalent in women who have had a
first breast cancer than in the general population [28,29]
and genetic factors have a greater role in early-onset
cancers and multiple primary cancers. Consequently, the
etiologic role for a genetic factor, including its possible
interactive effect with environmental factors and other
genes, should be more evident [29,30]. Further, studies of
other tumor suppressor genes have suggested that
persons with mutations have a heightened risk after RT
exposure than those with wild-type alleles [31–35]. Lastly,
the high prevalence of substantial and quantifiable
exposure to ionizing radiation among women with a history
of first primary breast cancer makes this group particularly
worthy of study for understanding the etiology of
radiogenic cancers, something that is virtually impossible
with a conventional case-control study design for which
the population prevalence of the exposure is so low.
Demonstration of an interaction between a gene, or
genes, such as BRCA1 and/or BRCA2, and an environ-
mental exposure, such as radiation, will constitute an
important scientific and practical finding that will help to
elucidate the mechanism through which a genetic
characteristic can affect the risk for breast cancer. In
turn, this information will contribute to informed
decisions on the prudent use of RT in subgroups of the
female population.
Design
Sample and rationale
In the WECARE Study of gene–environment interactions
of second primary breast cancer, 700 women with
asynchronous bilateral breast cancer serve as cases, and
1400 women with unilateral breast cancer who were
diagnosed with their cancer at the time that the cases
were diagnosed with their first primary, and at the same
age, serve as controls. Eligible cases and controls must
have survived at least 1 year after their initial diagnosis of
breast cancer. All study subjects were identified,
recruited, and interviewed through five population-based
cancer registries, four in the USA (three Surveillance,
Epidemiology and End Results registries, namely Iowa, Los
Angeles County [CA], and Seattle [WA], and the Cancer
Surveillance Program of Orange County [CA]) and one in
Denmark (the Danish Cancer Registry). These registries
provided access to an ethnically, racially, and
geographically diverse group of women representative of
breast cancer cases from the reporting areas.
Women were eligible as cases if they met the following
criteria: (1) they were diagnosed between 1 January 1985
and 31 December 2000 with a first primary invasive
breast cancer that did not spread beyond the regional
lymph nodes at diagnosis and a second primary in situ or
invasive contralateral breast cancer diagnosed at least
1 year after the first breast cancer diagnosis; (2) they
resided in the same study reporting area for both
diagnoses; (3) they had no previous or intervening cancer
diagnosis; (4) they were under age 55 years at the time of
diagnosis of the first primary breast cancer; and (5) they
were alive at the time of contact, able to provide informed
consent to complete the interview and could give a blood
sample.
Our inclusion criteria were designed to create a high-
quality database and biorepository of young women with
breast cancer to address our specific aims and to facilitate
future gene–gene and gene–environment studies. We
included both incident and prevalent cases to improve our
statistical power and to minimize the number of institutions
required. Only young women with breast cancer were
included because they were more likely to be genetically
predisposed to breast cancer and to have had a greater
susceptibility to radiation-induced cancer; effects of
radiation on breast cancer decrease with increasing age
at exposure and are low after age 45 years. Although
ideally we would have therefore only included women
diagnosed with first primary breast cancer at a very early
age, the logistics of accruing 700 such young women with
bilateral breast cancer were not feasible; this restriction
would have required additional data collection sites and
would also have precluded our competing interest to
make the study results applicable to a broader population.
We selected 1985 as the earliest date for diagnosis of the
first primary to provide an adequate range of follow-up
while still ensuring that most treatment records would be
available. Our rationale for only including women who
were living was the high quality and quantity of DNA that
would be available from the blood (as opposed to that
from tumor tissue only, if available at all, for deceased
women) for the laboratory work as well as the high quality
of the self-reported risk factor information (as opposed to
the use of surrogate reports). To the extent that the genes
of interest are related to survival, this design, by including
both living and prevalent cases of breast cancer (both
‘cases’ and ‘controls’) in our studies, might have incurred
some survival bias. However, because the subjects were
drawn from existing cancer registries, with data (for
example, age and stage at diagnosis, radiation therapy,
race, and histology) on all cancer cases regardless of
whether or not they were WECARE Study participants,
we will have some ability to look at the potential impact of
survival bias on our conclusions. Even in the absence of
information on genotype, compared with most case-
control studies for which data are available only on those
that participate, the availability of these data on everyone
is an important advantage. Because the registries
included systematic follow-up and comprehensive
information on cancers only for residents residing in their
reporting areas, we imposed residency requirements for
the time at diagnosis of the first and second primaries. We
excluded women with a history of previous or intervening
cancer diagnosis (other than breast cancer) because the
Available online http://breast-cancer-research.com/content/6/3/R199treatment that they may have received for the previous or
intervening cancer adds analytic complexity and may
jeopardize comparability between cases and controls. The
first primary breast cancer must have been invasive;
however, the second primary can have been an in situ
carcinoma, because women with a history of breast
cancer are more likely to be closely monitored for a
second primary cancer. We excluded women with disease
beyond the regional lymph nodes at diagnosis because
any prevalent long-term survivors would be unique in
terms of their survival, making it difficult to find suitably
matched controls; further, this restriction reduced the
unlikely chance that a contralateral breast cancer was a
metastasis from the first primary. In conducting this study,
we relied on the Surveillance, Epidemiology and End
Results definition of second primary breast cancer and did
not initiate an independent review of the pathology or
medical records before assigning case status.
Controls in the WECARE Study had unilateral breast
cancer and were representative of the population at risk
for developing a second primary breast cancer; eligible
controls were individually matched to cases on year of
birth (5-year strata), year of diagnosis (4-year strata),
registry region, and race. They must have survived without
any subsequent diagnosis of cancer during the interval
that elapsed between the matched case’s first and
second breast cancer diagnoses. At the end of this
interval, the control must have had an intact CB and must
have been living in the registry region. Although
theoretically each case could also have served as a
control for intervals less than that which elapsed between
her first and second diagnoses, we chose to exclude
cases from the control pool because this simplified the
process of identifying and recruiting cases and controls
and introduced little selection bias when the pool was
large so that the selected cases represented only a small
percentage of the pool [36]. The registry data on breast
cancer diagnoses occurring between 1985 and 2001
were reviewed to identify all women who seemed to meet
the eligibility criteria for either case or control status, and
the 700 cases and 1400 controls needed to conduct the
WECARE Study were recruited from this group of women.
Recruitment efforts began with information contained in
registry files for cases in both the US and in Denmark.  In
the US, if a woman had moved, in order to trace, verify
vital status, and update contact information, we linked to
publicly available data from other external sources,
including national change of address files and mortality
files. Because some of the cases were diagnosed with
their first primary nearly 15 years ago, tracing these
women was challenging and time consuming. In Denmark,
these tracing efforts were minimized due to their
centralized registry requirements and readily available
contact information.
In the US, eligibility was verified by the data collection
centers through administration of a brief screening
questionnaire during the initial phone contact (after
physician permission and the receipt of a letter of
introduction to the study). In Denmark, medical records
are maintained centrally by the Danish Cancer Society,
which made it possible to determine eligibility through an
initial review of the medical records followed by a letter of
introduction. In the US no such centralized source of
medical records exists and abstracting in the various
treatment centers could not be undertaken until informed
consent had been obtained, which sometimes resulted in
substantial additional work to trace and then contact
women who were later determined to be ineligible to
participate.
Counter-matching and selection of cases and controls
In this study, matching was used to control for
confounding due to temporal variables and race, and a
technique known as ‘counter-matching’ was used to
improve the statistical efficiency of the design further [37].
Here we describe elements of the counter-matching as
implemented in the WECARE Study. A quantitative
treatment of its effect on statistical power is given later in
the text and a discussion of counter-matching, including
details about the implementation, is provided in the
Appendix. Because a binary indicator of whether or not a
woman received RT as treatment for her first breast
cancer was available from the cancer registries at the time
of selection of controls, we incorporated counter-matching
on the registry radiation treatment indicator (RRT)
(according to the registry records). In our counter-
matched design, each case and two matched controls
form a triplet, in which two members of each triplet are
RRT+ (RRT exposed) and one member is RRT– (RRT
unexposed).
Practically speaking, beyond the usual process of
producing individually matched recruitment lists, only one
additional step was required for counter-matching, namely
stratification by RRT status of the subpopulation of
controls that falls into the same individual matching
stratum of a particular case: (1) if the case being matched
was RRT+, a set of potential controls was randomly
selected from each RRT stratum and one control was
recruited from each set; or (2) if the case being matched
was RRT–, a set of potential controls was randomly
selected from the RRT+ stratum only and two controls
were recruited from this single list. This counter-matched
design resulted in higher variability in radiation dose than
random sampling and enhanced the efficiency of the study
for estimating the dose-response effect in exposed
women as well as gene–environment interactions involving
exposure to radiation. In particular, the probability that all
members of a counter-matched set have the same true RT
status is much smaller than for random sampling.
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available at the time of selection of cases and controls
was not as detailed or as accurate as the information that
is available through the extensive data collection and
dosimetry that were integral parts of the study. However,
for the purposes of counter-matching it is sufficient to
have only a surrogate for the information on exposure that
will actually be incorporated into the analysis. Gains in
efficiency are thus still realized, although these gains will
not be so large as they would be if error-free information,
or true RT exposure information, were available at the time
of selection of the controls [37,38].
Collection of data from interview and medical records
and blood collection and processing
All women were interviewed with the same pretested,
scripted telephone questionnaire that emphasizes the
ascertainment of events occurring during the ‘at risk’
period (time between first and second primary diagnosis,
or its equivalent), including known and suspected risk
factors for breast cancer that also antedated the ‘at risk’
period (such as detailed family, reproductive, and medical
history), health care use, and treatment. A study
phlebotomist was sent to each woman’s home to draw the
blood sample. These blood samples were in turn sent for
DNA extraction and processing, lymphocyte cryo-
preservation, genotyping, and, ultimately, storage in the
WECARE Study biorepository. Initially, we considered
collecting buccal cells in the event of a blood refusal, but
because the DNA yield would not be sufficient for the
mutational screening of all three genes, this approach was
not implemented. Medical records, pathology reports, and
hospital charts were used to collect detailed treatment
(chemotherapy, hormonal therapy, RT) and tumor charac-
teristics (including location in the breast, stage at diagnosis,
estrogen and progesterone receptor status, and histology).
A great deal of care has been taken to maintain strict
confidentiality of all information; only the data collection
site that contacts an individual knows her identity.
Personal identifiers have never been included in any
electronic or hardcopy transmission of data; archived data
and genetic information have been identified only by study
identification number. These identification numbers were
randomly generated for the WECARE Study and
incorporated no identifying information, including that
related to the case/control status of the individual, triplet
membership, center, or date of enrollment. Each data
collection center received Institutional Review Board
approval to enroll women in the study and to screen their
blood samples for BRCA status as well as unknown
genetic mutations. Protocols and consent procedures
were recently modified for compliance with guidelines
established by the Health Insurance Portability and
Accountability Act. This new legislation may have a
serious negative impact on future research that uses the
WECARE repository. For example, we face having to
anonymize all data, which would preclude continued
follow-up for survival as an endpoint.
Quantification of radiation dose
The aim of radiation dosimetry was to produce individual
dose estimates to the CB that are suitable for analysis.
Absorbed dose to the CB is a combination of radiation
directly from the primary beam, scatter off the collimators
and filters, and leakage through the head of the machine.
The CB dose depends on several factors, including field
configuration, tumor dose, use of wedge filter or beam
blocking, and radiation energy. For most treatments the
range of dose across the CB varies by a factor of 10 or
more from the medial to lateral aspect.
Radiation dose estimates were based on all radiation
therapy during the ‘at risk’ period, including therapy for
primary breast cancer, metastases, recurrences, and
benign conditions. For each patient, we collected all
available information on RT and the location of the breast
tumor to provide specific dosimetry for the risk estimates.
Sources of RT information included the following:
complete basic RT record, summary RT notes, medical
record notes and histories; operative reports (for
brachytherapy); and physician correspondence. A score
was assigned to each patient to indicate the level of
information received (1, complete record; 2, partial record;
3, notes or summary only; 4, registry/interview data only).
Individual dose estimates were derived from measurement
in tissue-equivalent phantoms. We molded Aquaplast [39]
shells of both breasts using women in treatment positions.
Shells were made for women with small, medium, and
large breasts to test the influence of patient size. The
shells were then filled with layers of tissue equivalent
material (Superflab), which held thermoluminescent
dosimeters. A total of 300–400 dosimeters were used in
the CB. The response of the dosimeters was calibrated
using an ionization chamber with a calibration traceable to
the National Institute of Standards and Technology.
The most common treatment technique was medial and
lateral tangential fields with or without a boost field to the
tumor bed. Dose to the CB was sometimes modified by
use of wedge filters (15, 30, 45, or 60 degrees). For
example, a 30 degree wedge results in a dose to the CB
about 25% higher than that with a 15 degree wedge.
Some patients were also treated with peripheral lymphatic
fields, including supraclavicular, axillary, and internal
mammary. Figure 1 presents the dose (cGy) to the CB
observed among the initial 360 study subjects.
Staff at MDACC were blinded as to the case/control
status of subjects; therefore, dosimetry data was reported
for all quadrants and the areola for all patients. For each
Available online http://breast-cancer-research.com/content/6/3/R199
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analysis the region of the breast that contained the CB
tumor in the case.
Approximately 7% of the patient records received to date
were incomplete in some aspect and 2% of patients had
all documentation missing. Missing information was
imputed from similar patients treatment at the same
hospital. A score reflected which patients had imputed
doses. Uncertainties in the CB doses resulted from
unknown treatment information that could result in errors
larger than 20%, although most uncertainties produced
errors of 10% or less.
Mutation carrier status determination
For all three of the current target genes (ATM, BRCA1,
and BRCA2), we used the same two-staged approach for
determining carrier status. First, all coding regions and
flanking intronic regions were screened for mutations or
polymorphic variants by denaturing high-performance
liquid chromatography (DHPLC), a mutation-screening
technique that resolves homoduplexes and hetero-
duplexes of DNA formed by variant and wild-type sequences
by high-performance liquid chromatography. This
technique purports a high degree of sensitivity and ease of
execution due to the lack of any need for significant
sample manipulation after amplification. In the second
stage, all variant DHPLC results were followed up by
direct nucleotide sequencing of the appropriate
amplicons. Because of the size of the WECARE study
population and the complexity of the genes under study,
five laboratories performed the screening using the same
fixed set of protocols. To ensure consistency in screening
between and within laboratories, we established a
laboratory quality control plan that includes the following:
(1) blinded screening of an initial set of 19 samples,
including both samples with known mutations and
controls by all laboratories; (2) initial screening of the
same randomly selected 46 WECARE Study samples by
all laboratories; (3) rescreening by one laboratory of a
randomly selected 10% sample of all cases screened at
each of the participating laboratories; and (4) blinded
rescreening of a random 10% sample of each laboratory’s
own sample by that same laboratory. A more thorough
consideration of the issues involved in designing quality
control for a distributed screening approach as it applies
to the WECARE Study is available [40].
Statistical considerations in using the counter-matched
design
Several investigations have shown that counter-matching
on a correlate of exposure is more efficient than simple
random sampling for assessing exposure dose–response
and gene–exposure interactions over a wide range of
situations [37,41–43].
To assess the feasibility of possible case-control designs,
using an incident series of second primary breast cancer
cases as cases and incident first primary breast cancer
cases as controls, we calculated the statistical power
needed for detecting interaction terms of interest for
various levels of allele frequency. To make these power
calculations, we performed a limited simulation study
using the paradigm of risk set sampling: for each case,
two controls would be selected from those at risk at the
time of the case’s second (contralateral) breast cancer
diagnosis who matched the case on all factors (for
example, race, age at diagnosis, and registry region). Each
Breast Cancer Research    Vol 6 No 3 Bernstein et al.
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Figure 1
Range of quadrant doses (cGy) expected in the WECARE Study. Doses were calculated from phantom-derived measurements. Range limits were
chosen to correspond to the techniques being used among the WECARE subjects that would result in the lowest and highest doses to each
quadrant and the nipple area of the contralateral breast.risk set consisted of 100 subjects with covariates
generated as follows. RRT status was generated as a
Bernoulli trial with 40% probability of RRT+; this
approximates the observed percentage. True RT was then
(randomly) determined according to the given predictive
positive (PP) and predictive negative (PN) probabilities.
These were taken to be either PP = 100%, PN = 100%
(perfect agreement) or PP = 90%, PN = 90% (low agree-
ment), a range of accuracy in the RRT treatment
information that we believe spans the true accuracy [44].
For subjects actually given RT, a dose was assigned from
a  χ2 distribution with four degrees of freedom. This
distribution was used because it reasonably approximates
the dose distribution shape we expect to see in treated
subjects on the basis of previous data.
A case was randomly selected from the 100 risk-set
subjects with probability based on their assigned rate
ratios according to gene carrier status and radiation dose,
and the rate model. Seven hundred risk sets were
generated in this way. For the statistical power comparison,
controls were then drawn from each risk set in several
different ways. Random sampling of two or three controls
from the 99 in the risk set yields the standard 1:2 or 1:3
nested case-control study (NCC 3 or NCC 4). The other
two methods were to counter-match the two controls by
RRT status in two different configurations; with one
subject from the ‘untreated’ and two from the ‘treated’
(CM 1:2) or vice-versa (CM 2:1). The statistical power
estimates were based on 200 simulated data sets for
each set of parameters.
Statistical power for dose response
For computing the statistical power for detecting the
effect of radiation dose on the rate of second breast
cancer in the absence of gene susceptibility, the rate ratio
was taken to be log-linear as a function of dose and was
parameterized by the rate ratio at the 95th centile of the
dose distribution. Preliminary data indicated that this
corresponds to 2–3 Gy; conservatively, we call this the
2 Gy rate ratio. The 2 Gy rate ratio was taken to be 1.5 on
the basis of the findings of Boice and colleagues [27].
Table 1 shows the estimated statistical power for detect-
ing a radiation dose-response in the absence of gene
susceptibility according to the different design scenarios.
Included in this table are estimates for ‘full cohort
statistical power’ (noted as ‘All’ in the table) where
radiation dose would be available for all controls in the risk
set and used in an analysis. The two columns for CM 1:2
show the power of this design when RRT and true RT
status are in ‘perfect’ and ‘low’ agreement, respectively.
There is some loss of statistical power between perfect
and low agreement situations, but this loss is no more
than 5%. Comparing the CM 1:2 columns with the
randomly sampled controls, it is clear that, even with low
RRT–true RT agreement, counter-matching provides
much higher power than two (NCC 3) or even three
(NCC 4) randomly sampled controls. As seen in the final
column, and as would be expected on the basis of the
reduced within-set variability in radiation dose for sets
sampled in this way (see the discussion in the Appendix),
CM 2:1 has lower statistical power than the CM 1:2
design.
Statistical power for detecting gene susceptibility
Although it is reasonable to define ‘gene susceptibility’ as
a differential risk associated with an exposure in gene
mutation carriers compared with non-carriers, not enough
is known about the biological mechanisms between
ionizing radiation and mutations in DNA repair genes to
predict any particular mathematical form for the statistical
interaction that we might observe [45]. In particular, there
is some ambiguity (and controversy) about how to define
an interactive effect between two factors that are
Available online http://breast-cancer-research.com/content/6/3/R199
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Table 1
Statistical power (percentages) to detect a log-linear trend from various designs for 700 risk sets
Counter-matching
Random sampling CM 1:2 CM 2:1
2 Gy rate ratio Alla NCC 3 NCC 4 PN = 100%, PP = 100% PN = 90%, PP = 90% PN = 100%, PP = 100%
1.4 79 61 63 70 67 63
1.5 87 69 78 84 80 78
1.6 97 86 93 95 92 92
1.7 100 95 97 99 96 97
CM 1:2, counter-matched design in which one member of the triplet is registry radiation treatment negative (RRT–) and two are registry radiation
treatment positive (RRT+); CM 2:1, counter-matched design in which two members of the triplet are RRT– and one is RRT+; NCC 3, nested case-
control study in which each case is randomly matched to two controls; NCC 4, nested case-control study in which each case is randomly matched
to three controls; PN, predictive negative value; PP, predictive positive value. aFull cohort power where radiation dose is available for all controls in
the risk set and used in the analysis; this is the upper limit on any case-control analysis.individually associated with disease (that is, that have
‘main effects’) [46–48]. We note that once we have
additional data on genes that lie in the multiple DNA
damage response pathways, we will be able to make
empirical comparisons between the feasibility of testing
associations within causal pathways and associations
focused on the effect of single mutant alleles. Here, we
consider a situation that would be clearly seen as an
indication of biologic gene susceptibility; namely, when
there is no main effect of mutation, but the effect of
radiation is different in mutation carriers and non-carriers.
Specifically, the 2 Gy rate ratio was taken to be 1.5 in
mutation non-carriers, carriers were assumed to have no
additional risk if unexposed, and mutation by radiation
exposure effect was parameterized by the multiplicative
interaction at 2 Gy exposure. For example, an interaction
rate ratio of 5 would mean that mutation carriers who
receive a dose of 2 Gy have 1.5 × 5 = 7.5 times the rate
of second breast cancer compared with non-radiation-
treated subjects. Table 2 shows selected power results
for detecting gene mutation–radiation interaction. The
prevalence of BRCA1, BRCA2, and ATM mutations in the
general population is low, roughly 0.5–1% combined
across all genes, but may be as high as 10% among
breast cancer cases [12]; thus we present the power
estimates for several mutation prevalence levels. Focusing
on the CM 1:2 design actually used in the WECARE
Study, if the proportion of gene carriers is 1%, 80%
power is achieved only for interaction rate ratios of at least
20. The required rate ratio drops quickly with increasing
proportion of gene carriers, and 80% statistical power is
achieved at an interaction rate ratio of 8 with 3% gene
carriers. There is generally little change in power between
NCC 3 and CM 1:2 across perfect and low RRT–true RT
agreement. Comparing the different designs, CM 1:2 is
generally more powerful than simple random sampling
NCC 3, and often much more so. In particular, the power
advantage is greatest with rare genetic mutations. For
comparison, the CM 2:1 design is included and is seen to
do poorly, as one might expect on the basis of the
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Table 2
Statistical power for detecting a gene by radiation dose interaction from various study designs
Proportion of gene carriers = 0.5% Proportion of gene carriers = 1%
Study design PP = 100%, PN = 100% PP = 90%, PN = 90% PP = 100%, PN = 100% PP = 90%, PN = 90%
Int RR at 2 Gy 70 100 70 100 16 20 16 20
NCC 3 51 55 48 59 56 63 65 71
CM 1:2 66 67 68 73 75 80 74 76
CM 2:1 32 31 43 45 37 47 48 51
Proportion of gene carriers = 2% Proportion of gene carriers = 3%
Study design PP = 100%, PN = 100% PP = 90%, PN = 90% PP = 100%, PN = 100% PP = 90%, PN = 90%
Int RR at 2 Gy 8 10 8 10 6 8 6 8
NCC 3 67 84 68 84 73 88 74 89
CM 1:2 78 86 83 86 82 90 80 92
CM 2:1 58 69 71 73 63 79 67 81
Proportion of gene carriers = 5% Proportion of gene carriers = 10%
Study design PP = 100%, PN = 100% PP = 90%, PN = 90% PP = 100%, PN = 100% PP = 90%, PN = 90%
Int RR at 2 Gy 5 6 5 6 3 4 3 4
NCC 3 81 88 81 91 71 96 72 86
CM 1:2 88 92 88 94 70 95 74 93
CM 2:1 75 87 81 90 64 89 67 83
The power for detecting a gene by radiation dose interaction varies as a function of the proportion of gene carriers, interaction rate ratio at 2 Gy (Int
RR at 2 Gy), and predictive positive (PP) and predictive negative (PN) values for registry-noted radiation treatment for true treatment status. These
estimates are based on 700 risk sets on a simulation study with 200 trials for each set of parameters. The proportion of registry-noted radiation
treated is 40%, and the rate ratio for 2 Gy exposure in non-carriers is 1.5, which corresponds to the 95th centile of a χ2, four degrees of freedom
distribution. CM 1:2, counter-matched design in which one member of the triplet is unexposed and two are exposed; CM 2:1, counter-matched
design in which two members of the triplet are unexposed and one is exposed; NCC 3, nested case-control study in which each case is randomly
matched to two controls.radiation dose results. We note that in the 70–80%
statistical power range, an additional control in the
standard nested case-control design yields increases of
5–10% power. The CM 1:2 design, as was implemented
in the WECARE Study, provides this additional statistical
power at no additional up-front cost.
Analysis of radiation dose and gene susceptibility
We are currently preparing data for analysis. Our key
exposure variable is estimated radiation dose, which will
be treated as a continuous variable in the major analyses,
although a categorical approach will also be employed.
Analyses will be conducted using, for each case and her
matched controls, the estimated absorbed dose to the
specific quadrant in which the second primary arose in the
case. This approach might be more sensitive to errors in
the underlying model for estimating doses, but, if such
errors are small, it will be expected to give a more
accurate indication of the magnitude of risk for particular
levels of absorbed dose. Standard and biologically based
approaches to testing interactions (such as [49]),
including covariates for the main effects of gene carrier
status and radiation dose, together with their product to
test for the interaction effect, will be used. Similar
approaches could be used to investigate interactions
between genes or other factors. A detailed discussion of
the likelihood derivation software implementation for
analysis, and some examples using the SAS package
(SAS Institute, Cary, NC) are given in the Appendix.
Discussion
We designed the WECARE Study to maximize our ability
to examine the role of gene–environment and gene–gene
interactions in cancer etiology, not only for the three genes
that are currently under investigation but also for additional
genes that will be investigated in the future. The intensive
labor required to locate and enroll participants, to collect
the necessary treatment information, and to perform the
genotyping in large-scale population-based studies makes
the choice of a cost-efficient study design critical. In the
WECARE Study, we imposed the following criteria to
enhance the utility and increase the statistical power of
this resource beyond that obtained by a standard
population-based case-control study: (1) we restricted our
source population to women with breast cancer to ensure
a population enriched in the prevalence of germline
mutations which predispose to cancer; (2) we imposed a
young age at diagnosis requirement because of the age-
dependent effects of radiation to the breast; (3) we
quantified the radiation dose received by the CB during
therapy because it is sufficient to yield a substantial risk
for breast cancer (with doses being several hundred times
most diagnostic exposures); (4) we included a large
sample size of second primary breast cancers to ensure
adequate power for addressing interactions and other
comparisons of subgroups; and (5) we used a counter-
matched nested case-control design that makes use of
the available RRT information to increase efficiency over
random sampling.
As in any complex epidemiological study, given limited
time and resources, we have had to make compromises
on the scope of the study and the necessary number of
subjects to recruit, with the amount of environmental risk
factor information and biomaterial that we collected. We
have tried to be practical about what is necessary for our
immediate needs and to balance this with what we would
like to have available for future studies. For example, while
planning the biorepository we tried to predict some of the
future genetic and data analyses that we might be
interested in conducting. However, with the rapidly
changing field of molecular biology and with the Human
Genome Project well under way, our ability to foresee
what hypotheses will be relevant to address, even within
the next 5 years, is limited. So, to address the unknown
genetic mutations that we might be interested in testing
and to maximize the utility of the biorepository, we
cryopreserved lymphocytes for future transformation into
cell lines. For budgetary reasons, this choice meant that
we were unable to prepare RNA, which might limit future
analyses that we may wish to perform. Also, in theory, we
could have increased the precision of our radiation
exposure information by including measuring sources other
than RT; in particular, we could have included medical
exposures before the first breast cancer. However, it
seemed unlikely that the relatively small number of women in
our study for whom this information would be relevant would
justify the considerable cost and effort involved for retrieving
information of high enough quality as to be an improvement
over the information we gathered through the interview.
To determine whether a radiation-sensitive population of
women exists, in our study we will estimate and compare
the effects of radiation on the risk for developing
contralateral breast cancer in patients who are carriers of
certain mutant alleles in comparison with those who are
not. RT for treatment of breast cancer can result in
substantial exposure to the CB. Boice and colleagues [27]
showed that young women, 5 or more years after RT, were
most susceptible to radiation-induced second primaries; in
this study we therefore restricted the subjects to women
under the age of 55 years at diagnosis and included a
range of times between primaries to allow for the possibility
of an interaction that decreases the expected lag time.
Further, by using women exposed to high-dose RT, we
increased the likelihood of detecting a gene–radiation
interaction, if one exists. An important feature of our study
is that the radiation dose is quantifiable, enabling us to
examine dose–response relationships.
Although the restriction to a breast cancer patient
population limits some of the generalizability of our
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implications for our understanding the joint roles of genetic
susceptibility and radiation exposure in the etiology of
breast cancer in general. The mutation carrier prevalence
in the WECARE Study population was expected to be
higher than in a traditional case-control study in which the
controls are assumed to be cancer free, and so our
chances of detecting important associations with specific
mutations will be greater. Similarly, exposure to high levels
of ionizing radiation, such as that resulting from RT,
although rare in the general population, was common in
our population as a result of our counter-matched design:
two-thirds of the WECARE Study participants will have
received RT.
Conclusions
In this paper we have described the key elements of our
novel study design combining high-risk women with
quantifiable radiation exposure to allow the evaluation of
the potential interaction between genetic susceptibility
and ionizing radiation with the ultimate goal of
determining whether a radiosensitive subpopulation
exists. Although we focused on breast cancer and on
three genes, our counter-matched study design and
research methods are applicable to a broader range of
study aims and will help investigators to plan other similar
epidemiologic studies.
Appendix: Further discussion of issues
related to the counter-matched design
I. Issues related to implementing the counter-matched
design
Description of counter-matching as exposure-stratified
sampling from matched risk sets
Figure 2 shows a hypothetical and idealized implementa-
tion of the CM 1:2 counter-matched sampling for this
study, within a matching stratum defined by year of birth
(5-year strata), year of diagnosis (4-year strata), registry
region, and race/ethnicity. Each line represents a woman’s
duration on the study, with solid and dashed lines
indicating RRT– and RRT+ status, respectively. The filled
circle indicates that (and when) a woman developed a
contralateral breast cancer. Risk sets are defined as the
case and all eligible controls, controls being those women
who were observed to have been contralateral breast
cancer free at the case's time from first primary.  Controls
in each risk set in Figure 2 are indicated by short vertical
lines. Counter-matched controls (denoted by the open
circles) were sampled from those eligible so that the set
would have one RRT– and two RRT+ subjects. For
example, the first case was RRT+, so one RRT– control
was sampled from the 16 RRT– controls in the risk set
and one RRT+ is sampled from the 11 RRT+ in the risk
set. In the second instance, the case was RRT–, so two
controls were sampled from the 10 RRT+ in the risk set,
and so forth.
A little intuition and considerations in choosing the counter-
matched design
The motivation for using the counter-matched design is
based on the fact that in the regression setting, the
greater the variability in the covariates, the more precise
the regression parameter estimate becomes. CM 1:2 will,
on average, yield more radiation dose variability in the sets
than randomly sampled controls. This is because counter-
matched sets will typically have a subject with zero dose
and two that are from the dose distribution, whereas sets
with randomly sampled sets will be more likely to have two
or even three women who received no radiation treatment
(and thus zero dose). By the same reasoning, CM 2:1
would be less efficient than random sampling because
CM 2:1 sets would most frequently have two subjects
with zero ‘true’ dose, which will yield less radiation dose
variation than random sampling. Thus, the greater variation
in the RRT stratified (counter-matched) sets drives the
potential gain in information relative to random sampling.
In the WECARE Study situation, this intuition is confirmed.
The increased variation results in significant cost-
efficiencies for assessing radiation dose–response and
radiation–genotype interaction, as verified by the
simulation studies of power shown in Tables 1 and 2. We
note that although counter-matching can increase cost-
efficiency, counter-matched sampling on either unrelated
or poorly correlated variables will do worse than random
sampling. Thus, to realize an efficiency benefit through
counter-matching, the sampling stratum variable should be
fairly well correlated with the factor of interest. The
WECARE Study was designed to maximize the
information to assess radiation dose and gene–radiation
interactions at the ‘expense’ of power to investigate other
factors (such as main effects of gene; although, as it turns
out, the loss is relatively small). We decided that this
trade-off was worthwhile because the radiation gene
susceptibility question is of primary importance.
In practice, from a list of randomly selected potential
controls stratified by RRT status, the investigators at each
registry were sent a list of six RRT+ candidate controls if
the case was RRT–, and lists of three RRT– and three
RRT+ potential controls if the case was RRT+. For each
potential control, tracing techniques described in the
Design section were used to determine eligibility for the
study and, if eligible, the subject was invited to participate
in the study. For the first years of the study, potential
controls were assessed sequentially, proceeding to the next
potential control only when it was determined that the
current control was ineligible or declined to participate. In
the last year, we decided to process all potential controls
simultaneously and recruit the first two subjects who were
eligible and agreed to participate. Note that only the RRT
specific lists of potential controls distinguish this
implementation from that of many standard case-control
studies.
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data
Likelihood derivation
The appropriate likelihood contribution for CM 1:2 is
derived by a standard Bayes formula application as the
probability of observing the case given the RRT status and
covariates of subjects in the counter-matched set [37,50].
Thus, for the third counter-matched set in Fig. 2, consisting
of subjects 9, 18, and 24, the likelihood is given by
λ9 pr(18,24|9)/[λ9 pr(18,24|9) + λ18 pr(9,24|18) + 
λ24 pr(9,18|24)],
where, for example, λ9 is the probability that 9 is the case,
and  pr(18,24|9) is the probability that 18 and 24 are
sampled as controls given that 9 is the case. The values
for the components are given in Table 3. The λ values are
assumed to be from the proportional hazards model and
depend on the subjects’ covariates that we wish to model,
for example λ9 = λ0 r(Z9;β). The control selection
probabilities and weights depend on the number of RRT–
and RRT+ subjects in the risk set. Cancellation of
common factors yields a ‘weighted’ conditional logistic
likelihood contribution,
(8/2)r(Z9;β)/[(8/2)r(Z9;β) + 12r(Z18;β) + (8/2)r(Z24;β)], (A1)
in which a subject’s rate ratio contribution is multiplied by
an RRT ‘inverse sampling’ weight.
Data analysis
The only difference between an analysis of a counter-
matched sample and that of a simple random sample is
the inclusion of the weights in the model. This is easy to
do with most standard software packages. In particular,
consider the commonly used log-linear model, i.e. r(Z;β) =
exp(Zβ). Then, continuing our example, the likelihood
contribution (equation A1) for the third counter-matched
set equals
exp[Z9β + log(8/2)]/{exp[Z9β + log(8/2)] + 
exp[Z18β + log(12)] + exp[Z24β + log(8/2)]}. (A2)
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Figure 2
Counter-matching (CM) on registry radiation therapy (RRT) status. This figure shows a hypothetical and idealized implementation of the CM 1:2
samples for this study. The solid and dashed lines represent the time on study for RRT-unexposed (RRT–) and RRT-exposed (RRT+) subjects in a
matching stratum. Symbols: Filled circle, contralateral breast cancer case; short vertical line, women ‘at risk’ at the case’s time of contralateral
breast cancer who may serve as controls; open circle, counter-matched controls sampled from those at risk; number RRT+, number of RRT+
women in the risk set; number RRT–, number of RRT– women in the risk set.Thus, a log weight ‘covariate’ is always included in the
model with a coefficient fixed at one. To illustrate the
implementation, consider the hypothetical data set shown
in Table 4 that includes covariate data and corresponds to
the counter-matched sets illustrated in Fig. 2. Note that
these data are identical in structure to standard
individually matched case-control data with the variable
‘setno’ identifying case-control sets, ‘cc’ the case-control
indicator, and radiation treatment, genotype, and other
covariate data. But also included are the numbers of
RRT– and RRT+ subjects that are required for the
counter-matching weights. Table 5 shows the SAS code
that could be used in an analysis of radiation treatment
(yes/no) and of radiation–ATM gene mutation interaction.
The DATA step reads in the data and computes the log-
weight ‘logw’ and the interaction term ‘rad_atm_int’. The
PROC PHREG steps fit conditional logistic regression
models. The variable ‘setno’ is used as both the time and
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Table 3
Components of the counter-matched (CM) set likelihood calculation for third set illustrated in Fig. 2
Possible CM set configuration
Case Controls pr(case) Case RRT status pr(controls|case) Weighta
9 18, 24 λr(Z9;β) + 1/12 × 1/7 8/2
18 9, 24 λr(Z18;β) – 2/(8 × 7) 12
24 9, 18 λr(Z24;β) + 1/7 × 1/12 8/2
The calculation requires the probability of each of the possible case/control combinations, given that subjects 9,18, and 24 are in the counter-
matched set. pr(case) is the probability that the subject is a case based on the proportional hazards model. For instance, for subject 9, λ is the
baseline hazard, r(Z9;β) is the rate ratio based on the covariate value, and β is the rate ratio parameter. pr(controls|case) are control selection
probabilities. For example, for subject 18, because she is RRT–, pr(controls = 9,24|case = 18) is the probability of sampling two RRT+ from the 8
in the risk set. aWeights for analysis equal to pr(controls|case) × 12 × (8 × 7/2).
Table 4
Hypothetical data from the counter-matched sets depicted in Fig. 2
Number sampled  Total ATM
Subject  Case = 1/ RRT  from RRT  in RRT  True RT  Radiation  mutation 
Set no. ID control = 0 status stratum stratum status dose carrier status Chemotherapy
(setno) (id) (cc) (rrt) (m_rrt) (n_rrt) (true_rt) (rad_dose) (atm) (chemo)
11 2 0 0 1 1 60 0 0 1
1 3 1 1 2 11 1 250 0 1
11 6 0 1 2 1 11 4 0 0 0
25 1 0 1 1 6 0 0 1 1
2 25 0 1 2 10 1 110 0 0
2 22 0 1 2 10 1 100 0 1
3 18 0 0 1 12 1 220 0 1
39 1 1 2 81 4 0 0 1
32 4 0 1 2 8 1 6 1 0
42 3 1 0 1 1 10 0 0 1
4 2 0 1 2 7 1 170 1 0
41 9 0 1 2 7 0 0 0 0
51 0 0 1 10 0 0 1
5 2 1 1 2 1 1 250 0 1
The structure of the data is as in a standard matched case-control study, but the numbers in each of the sampling strata (n_rrt) are required for
analysis. The radiation dose is defined as the absorbed radiation dose (cGy) to quadrant in the contralateral breast where the case’s tumor was
located. Mutation carrier status is recorded as 0 = non-carrier, 1 = carrier. The status of chemotherapy administration as gathered from medical
record review is shown (0 = no chemo, 1 = chemo). ID, identification number; RRT, indicator of radiation therapy as derived from registry records
(registry RT; 0 = RRT–; 1 = RRT+); RT, status of radiation therapy administration as gathered from medical record review (True RT; 0 = TRT–, 1 =
TRT+).stratum variable; this is a standard trick to fit case-control
data with a Cox regression program. The term cc(0)
indicates that cc is the case-control indicator with 0
indicating a control. The ‘offset = logw’ option in the
model statement adds the log of the weights to the log-
linear model expression (as in equation A2) and this is
included in all analyses to account for the counter-
matched sampling design. The first PHREG run is to
estimate the rate ratio for radiation therapy (yes/no). Note
that the variable used in the analysis is ‘true_rt’, the
radiation therapy status as determined by interview with
the subject and review of medical records (rather than ‘rrt’,
the RT status recorded by the cancer registry and used for
the counter-matching). The second PHREG run is to fit an
interaction model for radiation dose and ATM mutation
carrier status. The interaction term ‘rad_atm_int’ captures
the relative difference in breast cancer rates associated
with radiation dose between ATM mutation carriers and
non-carriers.
We note that radiation effects are more appropriately
modeled as an excess rate ratio, r(Z;β) = 1 + Zβ, rather
than the log-linear relationship described above. Because
SAS allows only the log-linear model, for our actual
analysis we will use the package Epicure (Hirosoft
International, Inc., Seattle, WA), which accommodates a
richer class of rate ratio models (as well as incorporation
of the counter-matching weights).
Inaccuracies in RRT
As the ‘true_rt’ analysis in Table 5 indicates, the RRT
numbers used in the sampling weights are determined
only by the RRT status and do not change in any way once
we determine the ‘true’ RT status. Incorporation of the
RRT weights ensures that the analysis is valid regardless
of the accuracy of RRT for true RT status. However,
accuracy of RRT for true RT determines the precision with
which true RT and gene–RT interactions will be estimated,
as can be seen in the power analysis (Tables 1 and 2). As
discussed above, in the WECARE Study RRT is highly
correlated with true RT and yields a substantial cost-
efficiency benefit relative to random sampling.
III. Analytic issues that arise when the data are not
perfect
Inaccuracies in the weights
Another issue is that the actual numbers of at-risk RRT–
(N0) and RRT+ (N1) subjects is less than n0 and n1, the
RRT–/RRT+ numbers calculated from the WECARE
Study registry cohort, based on the number of potential
controls. The difference is due to the fact that the registry
numbers include women who have died, those who have
moved out of the study region, and those who may have
refused to participate. On the assumption that a subject in
the registry risk set was not in the actual risk set, did not
depend on RRT status, and is equal to π, then the
expected number of actual subjects is given by E[Nj] =
πnj. Replacing this expected value in the likelihood
contribution (equation A1), π cancels out and we are left
with the original weights. This suggests that using the
RRT numbers Nj without change yields a valid analysis.
Some limited simulation studies indicate that this
‘approximation’ works well. Further, because we have
systematically kept track of the numbers and reasons for
all non-eligibility, we will be able to empirically assess this
assumption that π does not depend on RRT, and if not,
could incorporate RRT (and possibly matching factor)
specific π.
Small matching strata
For some WECARE Study cases, only a few potential
control subjects, or even no controls for a particular case,
were available for recruitment. This was especially true for
women diagnosed at a young age. For example, in one
registry only 10 potential RRT– controls and 1 potential
RRT+ control were available for a Hispanic white RRT–
case whose first primary breast cancer was diagnosed
between ages 35 and 39 years, between calendar years
1985 and 1988. In this situation we did not have the six
RRT+ potential controls needed to implement the counter-
matched control selection protocol. In general, choosing
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Table 5
SAS computing code for counter-matched WECARE data
(wecare.dat) as illustrated in Table 4
data wecare;
infile ‘wecare.dat’;
input id setno cc rrt m_rrt n_rrt true_rt rad_dose atm chemo;
logw = log(n_rrt/m_rrt);
rad_atm_int = rad_dose*atm;
run;
* Radiation treatment yes/no, use true RT value;
proc phreg data = wecare;
model setno*cc(0) = true_rt/offset = logw;
strata setno;
run;
* Radiation-AT mutation interaction model;
proc phreg data = wecare;
model setno*cc(0) = rad_dose atm rad_atm_int/offset = logw;
strata setno;
run;
The input variables are as follows: id, subject identification no. (ID); cc,
case = 1/control = 0; rrt, Registry radiation therapy (0 = RRT–,1 =
RRT+); m_rrt, number sampled from RRT stratum; n_rrt, total in RRT
stratum; true_rt, true radiation therapy (0 = TRT–,1 = TRT+); rad_dose,
radiation dose; atm, ATM mutation (0 = non-carrier,1 = carrier); chemo,
chemotherapy (0 = no chemotherapy,1 = chemotherapy).the sampling method based on the risk set characteristics
will not result in biased estimation [37]. We therefore
decided on the following small-matching-stratum strategy.
1. If there were less than the required number of potential
controls in either of the RRT strata, we randomly
sampled a contact list of six potential controls,
assembled without regard to RRT status from all
potential controls and recruited two controls.
2. If fewer than six potential controls were available for
the case, all of the potential controls were included on
the contact list and, if possible, two were recruited. If
only one control was recruited, the set consisted of the
case and the single control.
3. If there were no potential controls available or when
none could be recruited, the age at diagnosis
matching criterion was expanded to include an
adjacent age category and controls were counter-
matched from this expanded stratum.
In the example provided, where only 10 RRT– and 1
RRT+ controls were available, method 1 applies: we
would randomly sample 6 potential controls from the 11
available, without regard to RRT status. This list would be
sent to the registry for tracing and the eventual recruitment
of two controls. The statistical analysis would be adjusted
to reflect these strategies; contributions from subjects in
sets with randomly sampled controls would be
‘unweighted’ in the conditional logistic likelihood.
Incomplete sets and missing covariate data
As is often the situation in case-control studies, there may
be some sets at the end of the data collection period that
have fewer than two controls for a given case, not
because of a lack of potential controls as in the small
matching stratum situation but because of tracing or
enrollment difficulties. A related problem is that some
controls may have partly missing covariate information. For
instance, we could have a case for whom radiation dose
could not be ascertained, but for whom genotype
information is available. A natural approach would be to
drop the case from the analysis, but this would result in
dropping the entire case-control triplet, a waste of the
control information. Although the number of such
incomplete sets due to either scenario should be small,
we use an approach of Huberman and Langholz [51] to
accommodate both problems. This method retains the
matching and counter-matching structure and provides a
modeling structure to handle the missing information using
‘missing indicators’. In the example above, a missing
indicator for genotype would be defined for all subjects in
the study and defined as 0 if genotype is known and 1 if
missing. The genotype variable(s) for subjects with
missing genotype would be set to the “baseline” values of
those variables. The missing indicator would then be
included in all analyses involving genotype. For the triplet
in which the case has missing genotype, this method
retains the genotype information from controls in the
triplet, as well as radiation dose information available on
the case. In the analysis, estimated parameters and
standard errors related to genotype and radiation are
interpreted as if all the data were present while the rate
ratio associated with the missing indicator is considered a
nuisance parameter and essentially ignored. Other
methods are possible, such as complete-case and
imputation, but we will explore such options as the need
arises.
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